Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.

Doycheva I, Thuluvath PJ.

J Clin Exp Hepatol. 2019 Sep-Oct;9(5):588-596. doi: 10.1016/j.jceh.2019.07.012. Epub 2019 Aug 2. Review.

PMID:
31695249
2.

Post-transplant Outcome of Lean Compared to Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.

Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, Kedia SK, Aithal GP, Bhamidimarri KR, Duseja A, Maiwall R, Maliakkal B, Jalal P, Patel K, Puri P, Ravinuthala R, Wong VW, Abdelmalek MF, Ahmed A, Thuluvath PJ, Singal AK; Global NAFLD Consortium.

Liver Transpl. 2019 Oct 30. doi: 10.1002/lt.25672. [Epub ahead of print]

PMID:
31665561
3.

Multiple regional listing increases liver transplant rates for those with MELD score less than 15.

Brown S, Savva Y, Barth R, LaMattina J, Thuluvath PJ.

Transplantation. 2019 Sep 18. doi: 10.1097/TP.0000000000002965. [Epub ahead of print]

PMID:
31568393
4.

Reversal of NASH fibrosis with pharmacotherapy.

Alukal JJ, Thuluvath PJ.

Hepatol Int. 2019 Sep;13(5):534-545. doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30. Review.

PMID:
31363910
5.

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics.

Chehl N, Maheshwari A, Yoo H, Cook C, Zhang T, Brown S, Thuluvath PJ.

Medicine (Baltimore). 2019 Jul;98(28):e16242. doi: 10.1097/MD.0000000000016242.

6.

Gastrointestinal Failure in Critically Ill Patients With Cirrhosis.

Alukal JJ, Thuluvath PJ.

Am J Gastroenterol. 2019 Aug;114(8):1231-1237. doi: 10.14309/ajg.0000000000000226.

PMID:
31185004
7.

Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis.

Bajaj JS, OʼLeary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Biggins SW, Lai JC, Vargas HE, Maliakkal B, Fallon MB, Thuluvath PJ, Subramanian RM, Thacker LR, Reddy KR.

Am J Gastroenterol. 2019 Jul;114(7):1091-1100. doi: 10.14309/ajg.0000000000000280.

PMID:
31180922
8.

Survival Outcomes Are Not Affected When Liver Transplant Surgery Is Done at Night, During Weekends, or Summer Months.

Thuluvath PJ, Amjad W, Savva Y, Thuluvath AJ, LaMattina J.

Transplant Direct. 2019 Apr 25;5(5):e449. doi: 10.1097/TXD.0000000000000887. eCollection 2019 May.

9.

Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR.

Aliment Pharmacol Ther. 2019 Jun;49(12):1518-1527. doi: 10.1111/apt.15265. Epub 2019 Apr 29.

PMID:
31032966
10.

Impact of Chronic Kidney Disease on Outcomes in Cirrhosis.

Wong F, Reddy KR, O'Leary JG, Tandon P, Biggins SW, Garcia-Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS.

Liver Transpl. 2019 Jun;25(6):870-880. doi: 10.1002/lt.25454. Epub 2019 Apr 25.

PMID:
30908855
11.

Endoscopic en bloc removal of appendiceal polyp facilitated by traction.

Kantsevoy SV, Thuluvath AJ, Raina A, Thuluvath PJ.

VideoGIE. 2019 Jan 17;4(3):136-139. doi: 10.1016/j.vgie.2018.11.009. eCollection 2019 Mar. No abstract available.

12.

Karnofsky Performance Status Following Liver Transplantation in Patients With Multiple Organ Failures and Probable Acute-on-Chronic Liver Failure.

Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T.

Clin Gastroenterol Hepatol. 2019 Mar 15. pii: S1542-3565(19)30280-0. doi: 10.1016/j.cgh.2019.03.016. [Epub ahead of print]

PMID:
30885883
13.

Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.

Bajaj JS, Tandon P, OʼLeary JG, Wong F, Biggins SW, Garcia-Tsao G, Kamath PS, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Vargas HE, Subramanian RM, Thacker LR, Reddy KR.

Am J Gastroenterol. 2019 Apr;114(4):599-606. doi: 10.14309/ajg.0000000000000044.

PMID:
30694868
14.

Reply to: "Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse".

Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y.

J Hepatol. 2019 Mar;70(3):549-550. doi: 10.1016/j.jhep.2018.10.013. Epub 2018 Nov 3. No abstract available.

PMID:
30396699
15.

Liver transplantation in patients with multiple organ failures: Feasibility and outcomes.

Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y.

J Hepatol. 2018 Nov;69(5):1047-1056. doi: 10.1016/j.jhep.2018.07.007. Epub 2018 Jul 31.

PMID:
30071241
16.

Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis.

Thuluvath PJ, Hanish S, Savva Y.

Transplantation. 2019 Jan;103(1):113-121. doi: 10.1097/TP.0000000000002355.

PMID:
29985186
17.

Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.

Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y.

J Hepatol. 2018 Oct;69(4):973-975. doi: 10.1016/j.jhep.2018.06.015. Epub 2018 Jul 5. No abstract available.

PMID:
29983203
18.

Karnofsky performance status before and after liver transplantation predicts graft and patient survival.

Thuluvath PJ, Thuluvath AJ, Savva Y.

J Hepatol. 2018 Oct;69(4):818-825. doi: 10.1016/j.jhep.2018.05.025. Epub 2018 Jun 6.

PMID:
29883596
19.
20.

NEWSworthy but Not Ready for Prime Time.

Thuluvath PJ.

Clin Gastroenterol Hepatol. 2018 Oct;16(10):1566-1568. doi: 10.1016/j.cgh.2018.03.023. Epub 2018 Mar 27. No abstract available.

PMID:
29596985
21.

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ.

J Hepatol. 2018 Aug;69(2):293-300. doi: 10.1016/j.jhep.2018.03.007. Epub 2018 Mar 16.

22.

Poor Survival After Retransplantation in NASH Cirrhosis.

Thuluvath AJ, Chen PH, Thuluvath PJ, Kantsevoy S, Savva Y.

Transplantation. 2019 Jan;103(1):101-108. doi: 10.1097/TP.0000000000002135.

PMID:
29470354
23.

Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for Complications of Cirrhosis.

Nuthalapati A, Schluterman N, Khanna A, Greenberg D, Thuluvath PJ.

J Clin Exp Hepatol. 2017 Dec;7(4):290-299. doi: 10.1016/j.jceh.2017.05.004. Epub 2017 May 13.

24.

Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis.

Thuluvath PJ, Hanish S, Savva Y.

Transplantation. 2018 Apr;102(4):656-663. doi: 10.1097/TP.0000000000002030.

PMID:
29215462
25.

Is cryptogenic cirrhosis different from NASH cirrhosis?

Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y.

J Hepatol. 2018 Mar;68(3):519-525. doi: 10.1016/j.jhep.2017.11.018. Epub 2017 Nov 21.

PMID:
29162389
26.

Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S.

Liver Int. 2018 May;38(5):821-833. doi: 10.1111/liv.13596. Epub 2017 Oct 12.

27.

Previous living donor hemihepatectomy as cadaveric donor of remnant liver.

LaMattina JC, Sultan S, Hanish SI, Bruno DA, Thuluvath PJ, Maheshwari A, Barth RN.

Liver Transpl. 2017 Oct;23(10):1348-1350. doi: 10.1002/lt.24804. No abstract available.

28.

Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes.

Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, Subramanian RM, Thuluvath PJ, Kamath PS, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj JS.

Am J Gastroenterol. 2017 Jul;112(7):1103-1110. doi: 10.1038/ajg.2017.122. Epub 2017 Apr 25.

PMID:
28440305
29.

Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study.

Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ; Vapreotide Study Group.

J Clin Gastroenterol. 2017 May/Jun;51(5):446-453. doi: 10.1097/MCG.0000000000000733.

30.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.

Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845.

31.

Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR.

Clin Gastroenterol Hepatol. 2017 Apr;15(4):565-574.e4. doi: 10.1016/j.cgh.2016.09.157. Epub 2016 Oct 5.

PMID:
27720916
32.

Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Thuluvath PJ, Nuthalapati A, Price J, Maheshwari A.

J Clin Exp Hepatol. 2016 Mar;6(1):3-9. doi: 10.1016/j.jceh.2015.09.003. Epub 2015 Oct 3.

33.

Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis.

Krok KL, Wagennar RR, Kantsevoy SV, Thuluvath PJ.

Arch Med Sci. 2016 Apr 1;12(2):365-71. doi: 10.5114/aoms.2016.59263. Epub 2016 Apr 12.

34.
35.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Rodriguez-Torres M, Läwitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.

Ann Hepatol. 2016 Nov - Dec;15(6):834-845. doi: 10.5604/16652681.1222098.

36.

The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.

Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas H, Thacker LR, O'Leary JG; North American Consortium for the Study of End-Stage Liver Disease.

Hepatology. 2016 Jul;64(1):200-8. doi: 10.1002/hep.28414. Epub 2016 Feb 19.

37.

Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.

Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT.

Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10.

PMID:
26551051
38.

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.

Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF.

Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 6.

PMID:
26473667
39.

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.

Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C.

Gastroenterology. 2015 Oct;149(4):971-80.e1. doi: 10.1053/j.gastro.2015.07.001. Epub 2015 Jul 11.

40.

Endoscopic suturing closure of large iatrogenic colonic perforation.

Kantsevoy SV, Bitner M, Davis JM, Hajiyeva G, Thuluvath PJ, Gushchin V.

Gastrointest Endosc. 2015 Oct;82(4):754-5. doi: 10.1016/j.gie.2015.05.031. Epub 2015 Jun 22. No abstract available.

PMID:
26112678
41.

Hyponatremia in cirrhosis: pathophysiology and management.

John S, Thuluvath PJ.

World J Gastroenterol. 2015 Mar 21;21(11):3197-205. doi: 10.3748/wjg.v21.i11.3197. Review.

42.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team.

Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.

43.

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, Webster L, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF.

J Hepatol. 2015 May;62(5):1204-6. doi: 10.1016/j.jhep.2014.12.025. Epub 2015 Jan 2. No abstract available.

44.

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

45.

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.

Tatum H, Thuluvath PJ, Lawitz E, Martorell C, DeMicco M, Cohen S, Rustgi V, Ravendhran N, Ghalib R, Hanson J, Zamparo J, Zhao J, Cooney E, Treitel M, Hughes E.

J Viral Hepat. 2015 Aug;22(8):658-64. doi: 10.1111/jvh.12372. Epub 2014 Dec 15.

PMID:
25496007
46.

Interventional procedures in hepatobiliary diseases.

Cárdenas A, Thuluvath PJ.

Clin Liver Dis. 2014 Nov;18(4):xiii-xiv. doi: 10.1016/j.cld.2014.08.001. Epub 2014 Sep 15. No abstract available.

PMID:
25438295
47.

Endoscopic retrograde cholangiography for biliary anastomotic strictures after liver transplantation.

Fernández-Simon A, Díaz-Gonzalez A, Thuluvath PJ, Cárdenas A.

Clin Liver Dis. 2014 Nov;18(4):913-26. doi: 10.1016/j.cld.2014.07.009. Epub 2014 Aug 22. Review.

PMID:
25438291
48.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
49.

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E.

J Hepatol. 2014 Dec;61(6):1220-7. doi: 10.1016/j.jhep.2014.07.011. Epub 2014 Jul 16.

PMID:
25038486
50.

Response.

Kantsevoy SV, Bitner M, Mitrakov AA, Thuluvath PJ.

Gastrointest Endosc. 2014 Aug;80(2):363-4. doi: 10.1016/j.gie.2014.04.017. No abstract available.

PMID:
25034848

Supplemental Content

Loading ...
Support Center